Alexion's Soliris Receives Positive Opinion from the Committee for Orphan Medicinal Products for Treatment of Neuromyelitis Optica

Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN ) today announced that Soliris® (eculizumab), the company's first-in-class terminal complement inhibitor, has received a positive opinion for orphan medicinal product designation from